 Jennifer Oliver
Concepts (100)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Meningococcal Vaccines | 2 | 2022 | 58 | 0.800 |
Why?
| | Respiratory Tract Infections | 5 | 2025 | 397 | 0.740 |
Why?
| | Haemophilus influenzae type b | 1 | 2020 | 12 | 0.650 |
Why?
| | Haemophilus Vaccines | 1 | 2020 | 29 | 0.640 |
Why?
| | Vaccines, Conjugate | 4 | 2024 | 60 | 0.520 |
Why?
| | Hospitalization | 7 | 2025 | 2433 | 0.460 |
Why?
| | Respiratory Syncytial Virus, Human | 2 | 2025 | 81 | 0.430 |
Why?
| | Respiratory Syncytial Virus Infections | 2 | 2025 | 136 | 0.410 |
Why?
| | United Kingdom | 9 | 2025 | 338 | 0.400 |
Why?
| | Community-Acquired Infections | 2 | 2025 | 174 | 0.370 |
Why?
| | Neisseria meningitidis | 3 | 2022 | 23 | 0.360 |
Why?
| | Meningococcal Infections | 2 | 2022 | 26 | 0.300 |
Why?
| | Pneumonia | 3 | 2025 | 631 | 0.290 |
Why?
| | Cotinine | 1 | 2007 | 79 | 0.260 |
Why?
| | Serogroup | 3 | 2024 | 44 | 0.240 |
Why?
| | Polymerase Chain Reaction | 3 | 2025 | 1054 | 0.240 |
Why?
| | Respiratory Syncytial Viruses | 1 | 2025 | 58 | 0.230 |
Why?
| | Saliva | 3 | 2025 | 249 | 0.230 |
Why?
| | Nicotine | 1 | 2007 | 331 | 0.210 |
Why?
| | Vaccines, Combined | 2 | 2023 | 49 | 0.210 |
Why?
| | Specimen Handling | 1 | 2025 | 186 | 0.210 |
Why?
| | Pneumonia, Pneumococcal | 1 | 2024 | 47 | 0.200 |
Why?
| | Smoking Cessation | 1 | 2007 | 439 | 0.200 |
Why?
| | Prospective Studies | 9 | 2025 | 7990 | 0.190 |
Why?
| | Pneumococcal Infections | 1 | 2024 | 103 | 0.190 |
Why?
| | Chickenpox | 1 | 2023 | 81 | 0.180 |
Why?
| | Respiration Disorders | 1 | 2022 | 77 | 0.180 |
Why?
| | Immunogenicity, Vaccine | 1 | 2021 | 36 | 0.170 |
Why?
| | Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2020 | 28 | 0.160 |
Why?
| | Poliovirus Vaccine, Inactivated | 1 | 2020 | 27 | 0.160 |
Why?
| | B-Lymphocytes | 1 | 2025 | 876 | 0.150 |
Why?
| | Antibodies, Bacterial | 1 | 2020 | 148 | 0.150 |
Why?
| | Influenza Vaccines | 1 | 2024 | 529 | 0.150 |
Why?
| | Meningitis, Meningococcal | 1 | 2019 | 6 | 0.150 |
Why?
| | Rabbits | 1 | 2020 | 648 | 0.150 |
Why?
| | Vaccines | 1 | 2023 | 389 | 0.140 |
Why?
| | Carrier State | 2 | 2019 | 79 | 0.140 |
Why?
| | Influenza, Human | 1 | 2024 | 616 | 0.140 |
Why?
| | T-Lymphocytes | 1 | 2025 | 1982 | 0.130 |
Why?
| | Incidence | 4 | 2025 | 2879 | 0.120 |
Why?
| | Adult | 12 | 2025 | 40449 | 0.120 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2023 | 920 | 0.120 |
Why?
| | Nasopharynx | 2 | 2025 | 73 | 0.110 |
Why?
| | Humans | 19 | 2025 | 144759 | 0.100 |
Why?
| | Emergency Service, Hospital | 1 | 2025 | 2310 | 0.100 |
Why?
| | Aged | 7 | 2025 | 25913 | 0.090 |
Why?
| | Young Adult | 6 | 2025 | 14105 | 0.090 |
Why?
| | Aged, 80 and over | 4 | 2025 | 8265 | 0.090 |
Why?
| | Adolescent | 7 | 2025 | 22428 | 0.080 |
Why?
| | Case-Control Studies | 3 | 2024 | 3604 | 0.080 |
Why?
| | Middle Aged | 7 | 2025 | 35875 | 0.080 |
Why?
| | Age Factors | 3 | 2024 | 3333 | 0.080 |
Why?
| | Antibodies, Viral | 2 | 2025 | 672 | 0.080 |
Why?
| | Vaccination | 3 | 2025 | 1423 | 0.070 |
Why?
| | Heart Failure | 1 | 2022 | 2323 | 0.070 |
Why?
| | Male | 9 | 2025 | 72315 | 0.070 |
Why?
| | Infant | 1 | 2020 | 10034 | 0.060 |
Why?
| | Corpus Striatum | 1 | 2007 | 179 | 0.060 |
Why?
| | In Vitro Techniques | 1 | 2007 | 1047 | 0.060 |
Why?
| | Receptors, Nicotinic | 1 | 2007 | 321 | 0.050 |
Why?
| | Dopamine | 1 | 2007 | 283 | 0.050 |
Why?
| | Female | 7 | 2025 | 78271 | 0.050 |
Why?
| | Sputum | 1 | 2025 | 308 | 0.050 |
Why?
| | Immunity, Cellular | 1 | 2025 | 272 | 0.050 |
Why?
| | State Medicine | 1 | 2023 | 27 | 0.050 |
Why?
| | Longitudinal Studies | 2 | 2025 | 2947 | 0.050 |
Why?
| | ABO Blood-Group System | 1 | 2023 | 57 | 0.050 |
Why?
| | Immunologic Memory | 1 | 2025 | 366 | 0.050 |
Why?
| | Pneumococcal Vaccines | 1 | 2024 | 130 | 0.050 |
Why?
| | Animals | 2 | 2020 | 38058 | 0.050 |
Why?
| | Temperature | 1 | 2025 | 679 | 0.050 |
Why?
| | Seroepidemiologic Studies | 1 | 2022 | 172 | 0.050 |
Why?
| | Streptococcus pneumoniae | 1 | 2024 | 177 | 0.040 |
Why?
| | Viral Envelope Proteins | 1 | 2022 | 98 | 0.040 |
Why?
| | Rats, Sprague-Dawley | 1 | 2007 | 2527 | 0.040 |
Why?
| | RNA, Viral | 1 | 2025 | 688 | 0.040 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2022 | 130 | 0.040 |
Why?
| | Seasons | 1 | 2024 | 556 | 0.040 |
Why?
| | Mass Vaccination | 1 | 2021 | 18 | 0.040 |
Why?
| | England | 1 | 2021 | 111 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2025 | 1985 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2022 | 496 | 0.040 |
Why?
| | Immunization Schedule | 1 | 2021 | 187 | 0.040 |
Why?
| | Portugal | 1 | 2019 | 10 | 0.040 |
Why?
| | Comorbidity | 1 | 2024 | 1658 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2022 | 5868 | 0.040 |
Why?
| | Rats | 1 | 2007 | 5597 | 0.040 |
Why?
| | Hospitals | 1 | 2023 | 730 | 0.030 |
Why?
| | Child | 3 | 2025 | 22633 | 0.030 |
Why?
| | Disease Progression | 1 | 2023 | 2847 | 0.030 |
Why?
| | Agglutination Tests | 1 | 2015 | 4 | 0.030 |
Why?
| | Epidemiologic Studies | 1 | 2015 | 68 | 0.030 |
Why?
| | Pharynx | 1 | 2015 | 59 | 0.030 |
Why?
| | Time Factors | 1 | 2025 | 7173 | 0.030 |
Why?
| | Antigens, Bacterial | 1 | 2015 | 125 | 0.030 |
Why?
| | Risk Factors | 1 | 2025 | 10779 | 0.020 |
Why?
| | Quality of Life | 1 | 2023 | 3185 | 0.020 |
Why?
| | Bacterial Proteins | 1 | 2015 | 955 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2021 | 11679 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2022 | 17066 | 0.010 |
Why?
|
|
Oliver's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|